{"id":"W2591457709","doi":"10.1200/jco.2013.31.6_suppl.13","title":"Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Aflibercept; Medicine; Docetaxel; Prednisone; Internal medicine; Bevacizumab; Hazard ratio; Clinical endpoint; Prostate cancer; Gastroenterology; Placebo; Oncology; Surgery; Randomized controlled trial; Urology; Cancer; Chemotherapy; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002063686,0.001290221,0.002538515,0.0004931737,0.0003935295,0.001032792,0.0008709606,0.001289193,0.003889942],"category_scores_gemma":[0.001512799,0.0004972107,0.001714872,0.0004597795,0.0008313464,0.0007855824,0.0003247304,0.00247765,0.0006101761],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007317875,"about_ca_system_score_gemma":0.0009031257,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00112333,"about_ca_topic_score_gemma":0.003489319,"domain_scores_codex":[0.9995372,0.0002659133,0.00002856134,0.0000663643,0.00003216006,0.00006976861],"domain_scores_gemma":[0.9992068,0.0001942262,0.0001995535,0.00006063085,0.00004083794,0.0002979188],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9621473,0.006028111,0.0009160363,0.0005363589,0.000875601,0.0000300066,0.00004928594,0.0003874601,0.001700076,0.00006233821,0.001085368,0.02618219],"study_design_scores_gemma":[0.900368,0.0935997,0.003531558,0.00005260215,0.0006318925,0.00008183272,0.00002346927,0.0003968665,0.0004146007,0.0001119983,0.0007731713,0.0000143058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9798703,0.0124815,0.0004693304,0.0008663556,0.0006087382,0.001948632,0.001217552,0.0001504698,0.002387217],"genre_scores_gemma":[0.9869965,0.004582753,0.001126218,0.0009451695,0.0005001794,0.001564145,0.001662785,0.00003087612,0.002591332],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003889942,"threshold_uncertainty_score":0.01301318,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1735149474490027,"score_gpt":0.4880195139565482,"score_spread":0.3145045665075455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}